Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
Vor Biopharma Adds RC298 to RemeGen License Deal
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year Slide
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Vor Biopharma Files Prospectus For Offering $150M Common Shares
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint
William Blair Initiates Coverage On Vor Biopharma with Outperform Rating
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Vor Bio To Participate in Upcoming September Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.